Navigation Links
Warner Chilcott Announces Secondary Equity Offering
Date:11/13/2009

ARDEE, Ireland, Nov. 13 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced a 20,000,000 share secondary offering of its ordinary shares by certain selling shareholders. The selling shareholders include funds affiliated with Bain Capital Partners, DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, L.P., certain other institutional investors and members of the Company's senior management. The offering is being conducted as a public offering pursuant to an effective shelf registration statement under the Securities Act of 1933. The Company will not receive any proceeds from the sale of the shares but will pay the expenses of the offering.

The offering is being made through an underwriting syndicate, led by Goldman, Sachs & Co., Morgan Stanley, Credit Suisse and J.P. Morgan. The co-managers of the offering are BofA Merrill Lynch, Barclays Capital, Citi, Deutsche Bank Securities and UBS Investment Bank.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be a sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made by means of a prospectus supplement and the accompanying prospectus only. Copies of the prospectus supplement and accompanying prospectus can be obtained by contacting Goldman, Sachs & Co., at 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, by telephone at 1-866-471-2526 or by emailing Prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. Incorporated, at 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, by telephone at 1-866-718-1649 or by emailing prospectus@morganstanley.com; Credit Suisse Securities (USA) LLC, at One Madison Avenue, New York, NY 10010, Attention: Credit Suisse Prospectus Department or by telephone at 1-800-221-1037; or J.P. Morgan Securities Inc., at 4 Chase Metrotech Center, Floor 04, Brooklyn, NY 11245-0001, Attention: J.P. Morgan Securities Inc. or by telephone at 1-718-242-8002.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the U.S. and Western European pharmaceuticals markets. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F

Forward Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and our Current Report on Form 8-K filed on November 2, 2009; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

SOURCE Warner Chilcott plc


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
4. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
5. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
6. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Milestone Scientific Announces Third Quarter 2009 Results
9. EF Johnson Technologies Announces Third Quarter Results
10. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
11. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):